Patents Assigned to Acticor Biotech
  • Patent number: 11692033
    Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: July 4, 2023
    Assignees: Acticor Biotech, Université Paris Cité, Université Paris-XIII, Inserm (Institut National de la Santé et de la Recherche Médicale), Université Paris-Saclay
    Inventors: Philippe Billiald, Martine Jandrot-Perrus, Gilles Avenard
  • Patent number: 10842870
    Abstract: The present invention relates to humanized anti-human GPVI antibodies and uses thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: November 24, 2020
    Assignees: ACTICOR BIOTECH, UNIVERSITE DE PARIS, UNIVERSITÉ PARIS-XIII, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE PARIS-SACLAY
    Inventors: Philippe Billiald, Martine Jandrot-Perrus
  • Publication number: 20190367608
    Abstract: The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
    Type: Application
    Filed: February 2, 2018
    Publication date: December 5, 2019
    Applicants: Acticor Biotech, Université Paris Diderot - Paris 7, Université Paris-XIII, Nserm (Institut National de la Santé et de la Recherche Médicale), Université Paris-Sud 11
    Inventors: Philippe BILLIALD, Martine JANDROT-PERRUS, Gilles AVENARD